AIM ImmunoTech Inc. - Intelligence Dossier

Ticker: Private (per brief; note: currently trades as OTCQB:AIM)
Stage: pre_ipo
NAICS: Not provided; likely 541714 (Biotechnology R&D)

Executive Summary

AIM ImmunoTech Inc. is a clinical-stage biopharmaceutical company specializing in the development of immune system modulators. Its lead product, Ampligen (rintatolimod), is an investigational double-stranded RNA drug designed to activate the innate immune system and is being studied for chronic fatigue syndrome (ME/CFS), various cancers, and viral diseases.

Government Reliance & Contracts

The company has a substantial reliance on U.S. federal funding for research and development. Key contracts and grants include:

• Department of Defense (DoD): Funding for studies of Ampligen in Ebola and other hemorrhagic fevers, and as a potential broad-spectrum antiviral.
• National Institutes of Health (NIH): Grants for ME/CFS research and cancer immunotherapy trials.
• BARDA: Engagements related to pandemic preparedness, including COVID-19 animal model studies. These contracts have historically provided a significant portion of the company's revenue and R&D support, creating a high dependency on government agency decisions.

Moats & Key Technology

Ampligen (rintatolimod): A double-stranded RNA molecule with a unique mismatched base-pair configuration, making it a selective TLR3 agonist. This mechanism stimulates both innate and adaptive immunity, potentially enhancing responses against tumors and viruses.

• Patent Portfolio: Composition of matter and method patents covering Ampligen and its uses, providing exclusivity.
• Regulatory Designations: FDA Orphan Drug status for multiple indications, including ME/CFS and various cancers, offering market exclusivity and development incentives.
• Safety Track Record: Extensive human use in trials and expanded access programs, with a well-characterized safety profile that reduces development risk compared to novel agents.

Capital & Shadow Backers

AIM ImmunoTech is a pre-IPO company according to the client brief, but it actually trades on OTC Markets (OTCQB: AIM) with a small public float. The company has funded operations through:

• Public Equity Offerings: Frequent direct stock sales and at-the-market (ATM) facilities, diluting existing shareholders.
• Government Grants/Contracts: Non-dilutive funding from DoD and NIH.
• Institutional Investors: Known biotech-focused funds, though no prominent “shadow backers” have emerged. The capital structure is typical of a micro-cap biotech, facing liquidity challenges and heavy reliance on retail and high-net-worth investors.

Recent Catalysts

Provided SEC Filings & News: The background data collected (e.g., Murphy Oil 8-K, TransparentBusiness 8-K, etc.) contains no information relevant to AIM ImmunoTech. No direct catalysts can be derived from this set.

Typical Catalysts (last 12-24 months based on public record):

• Announcements of trial initiations or data readouts (e.g., Phase 2/3 in pancreatic cancer, immune profiling in ME/CFS).
• Issuance of new patents or orphan drug designations.
• Government contract modifications or new DoD awards.
• Insider buying or management changes.
• Press releases concerning potential partnerships or licensing deals. For current decision-making, review the company's recent 8-Ks and press releases for material events.